HLA同种免疫对接受免疫抑制治疗的严重再生障碍性贫血临床结局的影响
该研究在5项前瞻性试验的444例接受免疫抑制治疗的严重再生障碍性贫血患者中,探讨HLA同种免疫的临床相关性。99例(22%)存在HLA同种免疫,其与更短的总生存期、对免疫抑制治疗的反应降低及克隆演化风险升高相关。单细胞RNA测序显示同种免疫患者补体介导通路和适应性免疫系统激活增强。
要点
- 444例接受免疫抑制治疗的严重再生障碍性贫血患者中,99例(22%)存在HLA同种免疫。
- HLA抗体存在与更短的总生存期、对免疫抑制治疗的反应降低及克隆演化风险升高相关。
- 数据提示HLA同种免疫是疾病结局的标志物,同种免疫患者补体介导通路和适应性免疫系统激活增强。
核心结论
- 数据提示HLA同种免疫是疾病结局的标志物。
- 同种免疫患者补体介导通路和适应性免疫系统激活增强,表明免疫区室之间存在相互联系。
研究设计与样本
- 研究纳入来自5项前瞻性试验的444例接受免疫抑制治疗的严重再生障碍性贫血患者,分析HLA同种免疫与疾病结局的相关性。
- 使用单细胞RNA测序分析同种免疫患者的免疫激活状态。
主要发现
- 444例接受免疫抑制治疗的严重再生障碍性贫血患者中,99例(22%)存在HLA同种免疫。
- HLA抗体存在与更短的总生存期相关。
- HLA抗体存在与对免疫抑制治疗的反应降低相关。
- HLA抗体存在与克隆演化风险升高相关。
- 单细胞RNA测序显示同种免疫患者补体介导通路和适应性免疫系统激活增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune aplastic anemia (iAA) frequently results in transfusion dependence on platelets and packed red blood cells, increasing the risk for complications. The most common immune-mediated cause for platelet-transfusion refractoriness is alloimmunization with HLA antibody (Ab) to nonself class I antigens. The clinical impact of the HLA alloimmunization has not been well studied in patients with iAA. We investigated the clinical relevance of HLA alloimmunization in our large cohort of patients with iAA from 5 prospective trials and correlated with disease outcomes. Of 444 patients with severe AA treated with immunosuppressive therapy (IST), 99 (22%) had HLA alloimmunization. The presence of HLA Ab was associated with shorter overall survival, reduced responses to IST and higher risk of clonal evolution. Our data suggest that HLA alloimmunization is a marker of disease outcome. Furthermore, using single-cell RNA sequencing, we show enhanced activation of both complement-mediated pathways and the adaptive immune system in alloimmunized patients, indicating an interconnection between immune compartments.
引用
- Durrani J, Chen LN, Shalhoub RN, et al. Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy. Blood Adv. 2025. PMID: 40085951. doi:10.1182/bloodadvances.2024015301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。